Junshi Biosciences receives approval for toripalimab in Singapore, showing promising results in cancer treatment.
From GlobeNewswire: 2025-03-26 21:00:00
Shanghai Junshi Biosciences Co., Ltd announced the approval of toripalimab in combination with cisplatin and gemcitabine for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in Singapore, making it the first approved immuno-oncology treatment for NPC in the country. The approval is based on the results from the JUPITER-02 study, showing a 48% reduction in disease progression risk and a 37% reduction in death risk with toripalimab. The drug has been approved in over 35 countries and regions globally, aligning with the company’s ‘In China, For Global’ strategy. Junshi Biosciences is dedicated to developing innovative medicines to improve healthcare worldwide.
Toripalimab, an anti-PD-1 monoclonal antibody, has shown promising results in treating various cancers, including melanoma, nasopharyngeal carcinoma, urothelial carcinoma, and more. The drug has received approvals in China and international markets, with ongoing pivotal clinical trials covering a broad range of tumor types. Toripalimab has been approved in the US, the EU, India, and other countries, with additional applications under review globally. Junshi Biosciences, the company behind toripalimab, is committed to providing world-class, innovative drugs to patients worldwide, with a focus on cancer, autoimmune, metabolic, neurological, and infectious diseases.
Junshi Biosciences, an innovation-driven biopharmaceutical company, has a diverse pipeline of over 50 drug candidates across different therapeutic areas. The company’s products, including toripalimab, have received approvals in China and international markets, positioning Junshi Biosciences as a key player in the global pharmaceutical industry. With a mission to provide affordable and innovative drugs to patients worldwide, Junshi Biosciences remains dedicated to developing groundbreaking therapies for various diseases, including COVID-19.
Read more at GlobeNewswire: Junshi Biosciences Announces Toripalimab’s Approval in